Growth & profitability
- Revenue has grown 117.6% per year over the past 5 years.
- Operating margin has expanded, at 50.2% in the latest year.
SPRO Financials Spero Therapeutics, Inc.
11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | $9M | 0.0% | 50.2% | — | — | $40M |
| 2024 | $371000 | -$69M | 0.0% | -19773.9% | — | — | $53M |
| 2023 | $933000 | $23M | 0.0% | 2302.4% | — | — | $76M |
| 2022 | $3M | — | 0.0% | -1685.9% | — | — | $109M |
| 2021 | $3M | -$90M | 0.0% | -2865.5% | — | — | $113M |
| 2020 | $258000 | -$78M | 0.0% | -30664.0% | -$86M | — | $85M |
| 2019 | $5M | -$61M | 0.0% | -1333.1% | -$50M | — | $30M |
| 2018 | — | -$42M | — | — | -$42M | — | $34M |
| 2017 | — | -$39M | — | — | -$39M | — | $87M |
| 2016 | — | -$25M | — | — | -$30M | — | $10M |
| 2015 | — | -$10M | — | — | — | — | $6M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$7M | — | — | — | — | $56M |
| Dec '25 | $13M | $32M | 0.0% | 249.8% | — | — | $40M |
| Sep '25 | $0 | -$7M | — | — | — | — | $49M |
| Jun '25 | $0 | -$2M | — | — | — | — | $31M |
| Mar '25 | $12000 | -$14M | 0.0% | -122758.3% | — | — | $49M |
| Dec '24 | $52000 | -$21M | 0.0% | -41778.8% | — | — | $53M |
| Sep '24 | $65000 | -$17M | 0.0% | -28604.6% | — | — | $76M |
| Jun '24 | $114000 | -$18M | 0.0% | -16720.2% | — | — | $64M |
| Mar '24 | $140000 | -$13M | 0.0% | -9987.1% | — | — | $82M |
| Dec '23 | $223000 | $51M | 0.0% | 22660.1% | — | — | $76M |
| Sep '23 | $218000 | -$3M | 0.0% | -887.2% | — | — | $94M |
| Jun '23 | $269000 | -$12M | 0.0% | -4791.8% | — | — | $78M |
| Mar '23 | $223000 | -$13M | 0.0% | -6379.8% | — | — | $96M |
| Dec '22 | $278000 | — | 0.0% | 9325.2% | — | — | $109M |
| Sep '22 | $1M | -$12M | 0.0% | -1093.7% | — | — | $50M |
| Jun '22 | $896000 | -$29M | 0.0% | -2910.7% | — | — | $45M |
| Mar '22 | $247000 | -$33M | 0.0% | -12229.6% | — | — | $72M |
| Dec '21 | $256000 | -$29M | 0.0% | -10743.0% | — | — | $113M |
| Sep '21 | $708000 | -$23M | 0.0% | -3181.4% | -$5M | — | $113M |
| Jun '21 | $2M | -$19M | 0.0% | -880.4% | — | — | $72M |
Valuation over time
How the market has priced SPRO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 3.9× (Jan '24) to 13.6× (Jun '26).
- The price-to-sales ratio has fallen from 33.5× (Mar '23) to 9.3× (Jun '26).
P/E
P/S
Frequently asked questions
Is SPRO growing its revenue and profit?
Over the past 5 years, Spero Therapeutics, Inc.'s revenue has grown 117.6% per year. These are computed facts, not advice.
How much debt does SPRO have?
As of FY2025, Spero Therapeutics, Inc. reported — of total debt against $40M of cash.
What is SPRO's profit margin?
In FY2025, gross margin was —, operating margin 50.2%, and net margin 68.1%.
What is SPRO's P/E ratio?
As of Jun '26, Spero Therapeutics, Inc. traded at a price-to-earnings ratio of about 13.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.